Nippon Shinyaku.,Ltd. v. Sarepta Therapeutics, Inc.

CourtDistrict Court, D. Delaware
DecidedSeptember 24, 2021
Docket1:21-cv-01015
StatusUnknown

This text of Nippon Shinyaku.,Ltd. v. Sarepta Therapeutics, Inc. (Nippon Shinyaku.,Ltd. v. Sarepta Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nippon Shinyaku.,Ltd. v. Sarepta Therapeutics, Inc., (D. Del. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

NIPPON SHINYAKU CO., LTD., Plaintiff, V. C.A. No. 21-1015-LPS SAREPTA THERAPEUTICS, INC., Defendant.

MEMORANDUM ORDER WHEREAS, on July 13, 2021, Plaintiff Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”) sued Defendant Sarepta Therapeutics, Inc. (“Sarepta’) for breach of contract and various patent- related claims (see generally D.1. 2, 12); WHEREAS, Nippon Shinyaku simultaneously moved for a preliminary injunction, seeking to require Sarepta to withdraw seven petitions for inter partes review pending before the Patent Trial and Appeal Board (see generally D.1. 4, 13); WHEREAS, Nippon Shinyaku and Sarepta both requested that the Court hear oral argument on Nippon Shinyaku’s motion for a preliminary injunction (D.I. 26, 27); WHEREAS, Nippon Shinyaku subsequently requested that the Court expedite the scheduling of oral argument on its motion (D.I. 46); WHEREAS, the Court has carefully reviewed the briefing and other materials submitted in connection with Nippon Shinyaku’s motion (see generally D.1. 5, 14, 18, 23, 25, 30); NOW, THEREFORE, IT IS HEREBY ORDERED that Nippon Shinyaku’s motion for a preliminary injunction (D.I. 4) is DENIED.

To obtain a preliminary injunction, the movant must show: (i) “a reasonable probability of eventual success in the litigation,” and (ii) “that it will be irreparably injured . . . if relief is not granted.” Reilly v. City of Harrisburg, 858 F.3d 173, 176 (3d Cir. 2017). If those two factors are met, then courts may also consider: (iii) “the possibility of harm to other interested persons from the grant or denial of the injunction,” and (iv) “the public interest.” Id. Nippon Shinyaku has failed to persuade the Court that it is likely to succeed on the merits, that it will suffer cognizable irreparable harm in the absence of extraordinary preliminary relief, that the balance of harms tips in its favor, or that the public interest warrants the relief that it seeks. In due course, the Court will issue a memorandum that more fully explains its reasoning. IT IS FURTHER ORDERED that the parties’ requests for oral argument (D.I. 26, 27), including Nippon Shinyaku’s request for expedited scheduling of oral argument (D.I. 46), are DENIED. tel [| September 24, 2021 HONORABLE LEONARD P. sink Wilmington, Delaware UNITED STATES DISTRICT JUDGE

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Colleen Reilly v. City of Harrisburg
858 F.3d 173 (Third Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Nippon Shinyaku.,Ltd. v. Sarepta Therapeutics, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/nippon-shinyakultd-v-sarepta-therapeutics-inc-ded-2021.